Recommendations are moved to the static list when, after review, it is clear that no new evidence is likely to be published that would have any material effect on the current advice. Recommendations on the static list may be transferred back to the active review list if new evidence does become available that might effect the recommendation issued.
The following published AWMSG health technology assessment recommendations have been transferred to the static list. The list is ordered alphabetically by generic name or use the search box below to find a medicine by either generic or trade name, reference number, date or year, or any wording in the recommendation.
aclidinium bromide (Eklira® Genuair® ) Reference number: 938AWMSG recommendation: recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.Date first issued: 31/07/2013 argatroban (Exembol® ) Reference number: 1405AWMSG recommendation: recommended as an option for use within NHS Wales for anticoagulation in adult patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic therapy. The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test. However, such confirmation must not delay the start of treatment.Date first issued: 23/01/2013 atorvastatin (Lipitor® ) Reference number: 1480AWMSG recommendation: chewable tablets are recommended as an option for use within NHS Wales: • as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the Fredrickson classification) when response to diet and other non-pharmacological measures is inadequate. • to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable. • for the prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.Date first issued: 19/06/2012 bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy® ) Reference number: 3414AWMSG recommendation: recommended as an option for restricted use within NHS Wales. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy® ) is licensed for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy® ) is restricted for use to patients who are either unsuitable for or unable to tolerate dolutegravir/abacavir/lamivudine (Triumeq® ). Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy® ) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.Date first issued: 03/12/2018 bortezomib (Velcade® ) Reference number: 1254AWMSG recommendation: recommended as an option for use within NHS Wales:• for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation; • in combination with melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Date first issued: 23/01/2013 buprenorphine (Buvidal® ) Reference number: 3977AWMSG recommendation: recommended as an option for use within NHS Wales for the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.Date first issued: 18/09/2019 ceftaroline fosamil (Zinforo® ) Reference number: 1065AWMSG recommendation: recommended as an option for restricted use within NHS Wales. Ceftaroline fosamil (Zinforo®) should be restricted to use for the treatment of complicated skin and soft tissue infections in patients where methicillin-resistant S. aureus (MRSA) is suspected, only in the following settings: •For infections caused by Gram-positive pathogens, only if intravenous (IV) vancomycin or IV teicoplanin is inappropriate, has not been tolerated or treatment modification is required; and IV daptomycin or IV linezolid is normally used. •For mixed infections caused by common Gram-positive and Gram-negative pathogens (excluding extended-spectrum beta-lactamase-producing organisms, AmpC-producing organisms and non-fermenter Gram-negative organisms, such as Pseudomonas aeruginosa), only if IV vancomycin in combination with IV co-amoxiclav or IV teicoplanin in combination with IV co-amoxiclav is inappropriate, has not been tolerated or treatment modification is required; and IV daptomycin in combination with IV co-amoxiclav or IV linezolid in combination with IV co-amoxiclav is normally used. Ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Wales for the treatment of complicated skin and soft tissue infections outside of these settings. Ceftaroline fosamil (Zinforo®) is not recommended for use within NHS Wales for the treatment of community-acquired pneumonia.Date first issued: 31/07/2013 darunavir (Prezista® ) Reference number: 1383AWMSG recommendation: darunavir (Prezista®) 100 mg/ml oral suspension, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales, in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients, as well as antiretroviral therapy-experienced paediatric patients from the age of 3 years and at least 15 kg body weight.Date first issued: 13/07/2013 darunavir (Prezista® ) once daily Reference number: 1336AWMSG recommendation: darunavir (Prezista®) 800 mg once daily, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in antiretroviral therapy experienced adults with no darunavir resistance associated mutations and who have plasma HIV-1 RNA 100,000 copies/mL and CD4+ cell count ≥100 cells x 10⁶/l.Date first issued: 13/08/2012 dihydroartemisinin/piperaquine phosphate (Eurartesim® ) Reference number: 1228AWMSG recommendation: recommended as an option for use within NHS Wales for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more.Date first issued: 13/08/2012 dolutegravir/rilpivirine (Juluca® ) Reference number: 2850AWMSG recommendation: recommended as an option for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/ml) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non nucleoside reverse transcriptase inhibitor or integrase inhibitor. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.Date first issued: 19/12/2018 eplerenone (Inspra® ) Reference number: 763AWMSG recommendation: recommended as an option for use within NHS Wales in addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with New York Heart Association (NYHA) class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF ≤ 30%).Date first issued: 23/01/2013 fidaxomicin (Dificlir® ) Reference number: 847AWMSG recommendation: recommended as an option for restricted use within NHS Wales. Fidaxomicin (Dificlir®) should be restricted for use in the following subpopulations within its licensed indication for the treatment of adults with Clostridium difficile infections (CDI), also known as C. difficile-associated diarrhoea (CDAD): •Patients with severe CDI; •Patients with recurrence of CDI. Fidaxomicin (Dificlir®) should be prescribed on the advice of a consultant microbiologist, consistent with UK Health Security Agency guidance. Fidaxomicin (Dificlir®) is not recommended for use within NHS Wales outside the specified subpopulations..Date first issued: 13/12/2012 fosaprepitant (IVEMEND® ) Reference number: 3789AWMSG recommendation: recommended as an option for use within NHS Wales for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy.Date first issued: 03/12/2018 glycopyrronium bromide (Seebri® Breezhaler® ) Reference number: 1455AWMSG recommendation: recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.Date first issued: 22/05/2013 ipilimumab (Yervoy® ) Reference number: 3604AWMSG recommendation: recommended as an option for use within NHS Wales as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age to < 18 years of age. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.Date first issued: 02/11/2018 lanreotide (Somatuline® Autogel® ) Reference number: 1988AWMSG recommendation: recommended as an option for use within NHS Wales for the treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.Date first issued: 20/09/2018 levonorgestrel (Kyleena® ) Reference number: 3582AWMSG recommendation: recommended as an option for use within NHS Wales for contraception for up to five years.Date first issued: 20/09/2018 mercaptopurine (Xaluprine® ) Reference number: 1252AWMSG recommendation: 20 mg/ml oral suspension is recommended as an option for use within NHS Wales for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.Date first issued: 25/10/2012 nevirapine (Viramune® ) Reference number: 1581AWMSG recommendation: nevirapine (Viramune® ) prolonged release tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults, adolescents, and children three years and above and able to swallow tablets. Prolonged release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate release tablets or oral suspension should be used. Most of the experience with Viramune® is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune® should be based on clinical experience and resistance testing..Date first issued: 27/07/2012 octreotide (Sandostatin® LAR® ) Reference number: 3732AWMSG recommendation: recommended as an option for use within NHS Wales for the treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.Date first issued: 20/09/2018 ramipril oral solution Reference number: 1639AWMSG recommendation: Ramipril oral solution is recommended as an option for use within NHS Wales for: •Treatment of hypertension. •Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with: manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease); diabetes with at least one cardiovascular risk factor. •Treatment of renal disease: incipient glomerular diabetic nephropathy as defined by the presence of macroalbuminuria; manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor; manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day. •Treatment of symptomatic heart failure. •Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.Date first issued: 13/11/2013 rilpivirine (Edurant® ) Reference number: 557AWMSG recommendation: recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml, in combination with other antiretroviral medicinal products.Date first issued: 27/07/2012 romiplostim (Nplate® ) Reference number: 3103AWMSG recommendation: recommended as an option for use within NHS Wales for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to < 18 years who are refractory to other treatments (for example, corticosteroids, immunoglobulins). This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.Date first issued: 05/03/2019 rufinamide (Inovelon® ) Reference number: 991AWMSG recommendation: recommended as an option for restricted use within NHS Wales. Rufinamide (Inovelon®) is licensed as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years of age and older. Rufinamide (Inovelon® ) is restricted for use where other adjunctive treatments have proved sub-optimal or have not been tolerated. Rufinamide (Inovelon® ) is not recommended for use within NHS Wales outside of this subpopulation.Date first issued: 25/06/2019 semaglutide (Ozempic® ) Reference number: 1842AWMSG recommendation: recommended as an option for restricted use within NHS Wales for the treatment of insufficiently controlled type 2 diabetes mellitus in adults as an add-on therapy to oral antidiabetic medicines or basal insulin. Semaglutide (Ozempic®) is not recommended for use within NHS Wales as monotherapy when metformin is considered inappropriate due to intolerance or contraindications.Date first issued: 02/11/2018 tenofovir disoproxil fumarate (Viread® ) Reference number: 1643AWMSG recommendation: recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected adolescent and paediatric patients, with nucleoside reverse transcriptase inhibitor (NRTI) resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (245 mg tablets) and aged 6 to < 12 years who weigh from 17 kg to less than 22 kg (123 mg tablets), 22 kg to less than 28 kg (163 mg tablets) and 28 kg to less than 35 kg (204 mg tablets). Tenofovir disoproxil (as fumarate) (Viread® ) 33 mg/g granules are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate. The choice of tenofovir disoproxil to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients.Date first issued: 15/08/2013 tenofovir disoproxil fumarate (Viread® ) Reference number: 1880AWMSG recommendation: recommended for use within NHS Wales for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis. Tenofovir disoproxil (as fumarate) (Viread® ) 33 mg/g granules are recommended for use within NHS Wales for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age for whom a solid dosage form is not appropriate with: compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis.Date first issued: 15/08/2013 tiotropium (Spiriva® Respimat® ) Reference number: 1842AWMSG recommendation: recommended as an option for use within NHS Wales as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.Date first issued: 03/12/2018 vildagliptin (Galvus® ) Reference number: 1393AWMSG recommendation: recommended as an option for use within NHS Wales for the treatment of type 2 diabetes in patients with moderate or severe renal impairment.Date first issued: 25/10/2012 vildagliptin (Galvus® ) Reference number: 1531AWMSG recommendation: recommended as an option for use within NHS Wales for the treatment of type 2 diabetes mellitus as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.Date first issued: 22/03/2013